Lidoject (Lidocaine Hydrochloride)

Lidocaine exerts its effect by blocking voltage‑gated sodium channels on neuronal membranes. This inhibition prevents sodium influx that is essential for the generation and propagation of action potentials, thereby halting nerve impulse transmission in the area where the drug is administered. The result is a reversible loss of sensation limited to the targeted tissue.

The appropriate dose of Lidoject is determined by the prescribing clinician based on the specific procedure, the size of the treatment area, and the patient’s age, weight, and overall health. Only a qualified healthcare professional should calculate and administer the amount, adhering to established maximum lidocaine dosage guidelines.

Safety data for lidocaine in pregnancy and lactation are limited, and the product is classified as category unknown. Consequently, Lidoject should only be used when the potential therapeutic benefit justifies any possible risk to the fetus or nursing infant, and the decision should be made by a qualified obstetric or pediatric specialist.

To place an order, visit the product page on gnhindia.com, submit an enquiry with the required quantity, and provide institutional or trade credentials. GNH India’s procurement team will verify the information, then respond with pricing, availability, shipping details—including any cold‑chain requirements—and the necessary import documentation.

Compared with other amide‑type local anesthetics such as bupivacaine, lidocaine offers a faster onset of action and a moderate duration of anesthesia, making it suitable for short‑duration procedures. Its safety profile is well‑established, though its duration is shorter than that of longer‑acting agents, which may be preferred for extended surgeries.

Lidoject should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. Protect the product from direct sunlight, moisture, and extreme temperature fluctuations. Before use, inspect the solution for clarity and any particulate matter; discard if discoloration or contamination is observed.

Lidoject is administered by a trained healthcare professional via intradermal injection. The injection site is typically cleansed with an antiseptic, and a small gauge needle is used to deposit the solution into the superficial dermal layer. The volume injected depends on the size of the area to be anesthetized and the clinical protocol.

The most serious risks include systemic lidocaine toxicity, which can manifest as cardiovascular complications (arrhythmias, cardiac arrest) and central nervous system effects (seizures, loss of consciousness). Severe allergic reactions such as anaphylaxis and rare cases of methemoglobinemia also represent critical concerns that require immediate medical intervention.

Lidoject should be avoided in individuals with a known hypersensitivity to lidocaine or other amide‑type local anesthetics, patients with severe cardiac conduction abnormalities, uncontrolled arrhythmias, or those receiving concurrent class I antiarrhythmic drugs. Caution is also advised for patients with significant hepatic impairment, as metabolism may be reduced.